stockrowPalvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.
- EPS
- −76.7%
- Free cash flow
- −136.4%
Quarter to June 2026, against a year earlier
Follow PVLA
Alert me
Palvella Therapeutics, Inc. (PVLA) Book value per share
Palvella Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was 2.5×, down 91.2% from 28.1× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 15.1×. Over the past ten years it has ranged from −2.2× (fiscal 2023) to 81.2× (fiscal 2019); the current reading is higher than 18% of that period. Palvella Therapeutics, Inc. ranks 52nd of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 2.5× | (91.16%) |
| FY2024 | 28.1× | — |
| FY2023 | −2.2× | — |
| FY2022 | 30.1× | (52.12%) |
| FY2021 | 62.9× | 38.08% |
| FY2020 | 45.6× | (43.86%) |
| FY2019 | 81.2× | 34.83% |
| FY2018 | 60.2× | 186.84% |
| FY2017 | 21.0× | (56.63%) |
| FY2016 | 48.4× | (33.18%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 15.1× | (14.91%) |
| Mar 2026 | 17.8× | 613.80% |
| Dec 2025 | 2.5× | (28.86%) |
| Sep 2025 | 3.5× | (19.12%) |
| 42 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| PVLA Palvella Therapeutics, Inc. | 15.1× |
| CLDX Celldex Therapeutics, Inc. compare | 9.2× |
| VCEL Vericel Corporation compare | 7.5× |
| VERA Vera Therapeutics, Inc. compare | 5.7× |
| PHVS Pharvaris N.V. compare | 5.1× |
| AUPH Aurinia Pharmaceuticals Inc compare | 4.9× |
| IMNM Immunome, Inc. compare | 4.6× |
| ADMA ADMA Biologics Inc compare | 2.0× |
| BHVN Biohaven Ltd. compare | −0.7× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on PVLA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement